Some investment opportunities are obvious because the problem is huge. Others stand out because the problem is deeply personal, clearly defined, and still largely unsolved. indi is one of those rare businesses that sits in both camps.

The statistics on childhood developmental delay are confronting. Roughly one in five children experiences a delay before the age of six and for many of these families the journey quickly becomes complex, fragmented, and exhausting. A child can end up under the care of five, six, or even ten different clinicians, each holding only part of the picture. In practice, the parent becomes the project manager of a system they never asked to run.

That is the problem indi exists to solve.

A better way to coordinate care

indi is a software platform that brings parents and allied-health clinics onto the same page. It gives families a co-pilot app to capture concerns, observations, milestones, and documents in one place, while giving clinicians a shared workspace that improves visibility, communication, and coordination across the care journey.

What made this interesting from our perspective as an investor was the shape of the solution. indi is not trying to replace clinicians or abstract away the complexity of care. It is embedding itself into the workflow of clinics and then extending that value to the families they already serve. We believe this makes the product more useful, the distribution more efficient, and the network effect more credible.

This is a B2B2C model with real commercial logic. Clinics adopt the platform, families are brought into the workflow, and the product becomes more valuable as more of the care team engages with it. That is the kind of structure we like to see because it gives the company a path to scale without relying purely on expensive direct-to-consumer acquisition.

Why we invested

We backed indi because the company is solving a real problem in a market that is both emotionally resonant and commercially fragmented. The need is obvious once you understand the day-to-day reality of families navigating developmental care. The workflow challenge is equally obvious once you understand how clinics operate. We like how indi sits at the intersection of both.

That matters, because businesses that solve pain on both sides of a market are often the ones that can become durable platforms. Parents want clarity and coordination. Clinics want better communication, richer context, and a simpler way to manage ongoing care. indi is building for both, which makes the product stickier than a single-sided tool.

We always ask the “why now” question. Allied health waitlists in Australia have grown sharply since the pandemic, with speech therapy and occupational therapy among the most heavily impacted disciplines. The NDIS participant base has more than doubled in five years, and families navigating developmental care are now managing longer, more complex journeys across more providers than ever before, making the coordination problem more acute, not less.

Allied health is also at an inflection point where AI, workflow software, and parent-centred care are converging. The category is ready for a product that does more than store information. It needs to organise it, surface it, and make it useful in practice. indi is designed around exactly that.

Why this team

A good story is not enough. In early-stage investing, the question is always whether the founders can turn insight into execution. On that front, indi gives us confidence.

Orrin Benford brings rare founder-market fit. He is a second-time founder, but more importantly, he has lived the problem. His own family experience gave him firsthand exposure to the fragmentation that families face, and he has used that insight to build a product with real empathy and urgency behind it. That kind of motivation matters, but it becomes even more compelling when it is paired with the ability to build.

Jeff Quach adds that capability. He has the technical background to develop an AI-native product, and more importantly, he understands how to translate product ambition into something that can work inside real operational environments. That is a critical strength in a category where the software must fit clinical workflow.

Personal fuel, commercial edge

The best companies often carry something personal in their name. In 1900, Emil Jellinek commissioned a new kind of car from Daimler and named it after his daughter, Mercedes. He didn’t know it then, but that name would become one of the most recognised in the world, not because of what it signified at launch, but because of what the product became over time.

Orrin named indi after his daughter too. Like Jellinek, he wasn’t making a branding decision. He was making a statement about what the company is really for, a product born from a father’s experience of a broken system, built so that other families don’t have to navigate it alone.

Not every company named after a daughter becomes Mercedes-Benz. But the ones that carry that kind of personal weight tend to be built differently. The motivation is harder to fake, the product instincts sharper, and the mission less likely to drift when things get hard.

indi’s market is broad, but the wedge is focused. The initial customer base is allied-health clinics, particularly in speech therapy and occupational therapy, where the pain point is immediate and the relationship with families is already ongoing. From there, the company can expand across related disciplines and deepen its workflow integration over time.

That is what makes the business interesting beyond the first sale. The long-term value here is in it becoming a fundamental part of the operating system for a child’s care journey.

What the recent investment says about the company

One of the strongest signals in a deal like this is who else chooses to stand behind it. Indi’s backers include us, Giant Leap and Antler. We believe this group of backers bring credibility, judgment, and operating experience, and that matters in an early-stage company where execution risk is still high.

Quality co-investors are often a proxy for several things at once: they have seen the founders up close, they understand the market well enough to take a view on its potential, and they are willing to commit meaningful attention alongside capital. That does not remove the risk in the business, but it does improve the quality of the signal.

For us, the presence of respected investors in the round reinforces the sense that indi is being built with discipline and intention. It is the kind of backing that gives confidence not only in the company’s ambition, but in the team’s ability to carry it forward.

Interested in deals like this?

For investors who like early-stage software with meaningful mission, clear product-market logic, and a team that has both conviction and competence, keep an eye on indi. The company is not chasing a vague future state. It is solving a specific coordination problem that is obvious once seen and painful to ignore.

If you’d like to explore upcoming opportunities, visit moocoo.vc/investment-opportunities or get in touch.

moocoo.vc